Bluezone partners with Inuvi as blood testing provider for T2 diabetes life cover

Shutterstock

Shutterstock

Bluezone has selected Inuvi as its health testing provider for the launch of its life insurance cover for people with Type 2 diabetes.

The health data company will provide finger-prick blood testing for individuals taking out Bluezone’s term life insurance for Type 2 diabetes.

Bluezone will use the results from the test to assess a customer’s blood glucose (HbA1c) levels, allowing it to provide the customer with personalised cover within days.

Earlier this month Bluezone launched its life insurance cover for customers with Type 2 diabetes as the first of a portfolio of policies aimed at helping people with chronic health conditions in the UK and overseas.

The insurtech’s digital solution offers individuals in the UK with Type 2 diabetes life insurance cover while also removing the need for lengthy form filling and required medical appointments previously required to secure a similar policy.

Inuvi said it was proud to have been selected as Bluezone’s laboratory blood testing partner to help make life insurance more accessible for millions of people with Type 2 diabetes.

Bluzone will use Inuvi’s application programming interface (API) platform and laboratory testing services to ensure an effective underwriting process, the firm said.

Via an API notification, Inuvi will send home testing kits to Bluezone customers within hours of a successful online application. Once taken, the customer sends their blood sample to Inuvi’s UKAS accredited laboratory for testing.

Results will be securely returned to Bluzone typically within 24 hours of receipt and they will then be used to assess the application and generate a final quote.

Inuvi commercial director Paul Nattrass said: “Inuvi is proud to be selected by Bluezone as its health test partner and help it on its mission to provide life insurance for individuals with Type 2 Diabetes.”

Bluezone chief growth officer David Packman, said the insurer was delighted with the partnership with the API driven platform and turnaround times being key factors.

 

Exit mobile version